Immunic (IMUX) stock price is $7.64, up 3.10% on the day, as of Oct 21, 2026. It has a market cap of $324.38Mn, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap324.38 Mn
P/E-2.91
Div. Yield0.00
Add ratio to table…
About
Immunic, Inc. is a late stage biotechnology company focused on developing oral small molecule therapies for neurologic and gastrointestinal diseases. The company is headquartered in New York City with its primary research and development operations in Gräfelfing near Munich Germany. It employs approximately 90 personnel as of November 3 2025. Immunic advances three product candidates: vidofludimus calcium IMU 838 for relapsing and progressive multiple sclerosis and…
Immunic, Inc. is a late stage biotechnology company focused on developing oral small molecule therapies for neurologic and gastrointestinal diseases. The company is headquartered in New York City with its primary research and development operations in Gräfelfing near Munich Germany. It employs approximately 90 personnel as of November 3 2025. Immunic advances three product candidates: vidofludimus calcium IMU 838 for relapsing and progressive multiple sclerosis and ulcerative colitis, IMU 856 for intestinal barrier restoration in celiac disease inflammatory bowel disease graft versus host disease and potential weight management, and IMU 381 as a next generation molecule for gastrointestinal indications. The company's strategy centers on targeting biologically relevant immunological targets with molecules that have distinct mechanisms of action. Vidofludimus calcium inhibits dihydroorotate dehydrogenase and activates the neuroprotective transcription factor Nurr1. IMU 856 modulates SIRT6 to promote epithelial regeneration and barrier function. IMU 381 builds on the company's chemical and pharmacological research platform to address additional gastrointestinal indications. Each program is supported by preclinical and clinical data that aim to demonstrate safety tolerability and therapeutic activity.
Immunic, Inc. currently does not generate revenue from product sales as it has no approved therapies on the market. The company anticipates future revenue will arise from the commercialization of its product candidates upon obtaining regulatory approval and achieving market acceptance. Revenue would be derived from sales of its oral therapies to patients and healthcare providers. As of September 30, 2025 Immunic held cash and cash equivalents of approximately $35,100,000. The company has raised net cash of approximately $496,300,000 from inception through September 30, 2025 via private and public equity offerings. Immunic expects to continue incurring operating losses while it advances its clinical programs and will require additional funding to sustain operations beyond the next twelve months. The company's liquidity position and ability to secure further financing are key factors influencing its near term outlook.
Immunic, Inc. operates in the competitive biotechnology sector focused on oral therapies for autoimmune and inflammatory conditions. The company differentiates itself through its mechanistic approach combining dihydroorotate dehydrogenase inhibition with neuroprotective and antiviral activities in its lead candidate and through its SIRT6 modulating strategy for intestinal barrier repair. It positions itself as a late stage developer with ongoing Phase 3 trials and supportive Phase 2 data aiming to address high unmet need in multiple sclerosis and gastrointestinal diseases. Immunic competes with other biotech and pharmaceutical companies that are developing oral or injectable therapies for similar indications. The company's competitive advantages include its proprietary chemical scaffolds, early clinical evidence of neuroprotective effects, and a pipeline that addresses both neurologic and gastrointestinal disorders with oral administration. Intellectual property protection for vidofludimus calcium extends to 2041 with potential patent term extension, providing a barrier to entry for rivals. These factors collectively support Immunic's goal of establishing a differentiated position in niche therapeutic areas.
Immunic, Inc. intends to serve patients suffering from relapsing and progressive multiple sclerosis ulcerative colitis celiac disease inflammatory bowel disease graft versus host disease and related gastrointestinal disorders. The company's therapies are designed for outpatient use and would be prescribed by neurologists gastroenterologists and other specialty physicians. Patient populations targeted by Immunic's programs represent significant unmet medical need with limited effective treatment options currently available. Successful commercialization would provide access to oral alternatives that could improve adherence and quality of life for chronic disease sufferers. The company also explores potential applications in weight management through IMU 856's effects on glucagon like peptide 1 levels and food intake observed in preclinical studies. Overall Immunic's customer base comprises individuals seeking novel oral treatments for chronic inflammatory and autoimmune conditions and the healthcare providers who manage their care.
Sector:HealthcareSector rationaleImmunic is a biotechnology company developing oral small molecule therapies for neurologic and gastrointestinal diseases, such as multiple sclerosis and ulcerative colitis. Its core business activity is the discovery and clinical development of pharmaceuticals, which falls squarely within the Healthcare sector.Industry:BiotechnologyBiotechnologyPrimaryImmunic is a biotechnology company researching and developing therapies derived from biological science, specifically targeting immunological targets for neurologic and gastrointestinal diseases. Its pipeline includes candidates like vidofludimus calcium (IMU 838) and IMU 856, which are currently in clinical stages.Classified using BQ-MICSCIK: 0001280776
Bull & bear
Investment Thesis
▲ Bull case
Immunic is positioned to capitalize on a significant unmet need in progressive multiple sclerosis (PMS) through vidofludimus calcium's demonstrated ability to drive confirmed disability improvement (CDI), not just slow worsening, as highlighted in the CALLIPER trial data. The late-breaking poster at CMSC 2026 introduced the Confirmed Disability Change (CDC) endpoint, which captures both worsening and improvement in a unified framework, revealing consistent favorability for vidofludimus calcium over placebo across ordinal categorical, time-to-event, and Markov state change models. This approach addresses a critical limitation in current MS trial design, where conventional endpoints ignore neuroprotective or restorative effects, potentially underestimating the drug's true benefit. By demonstrating statistically significant CDI alongside favorable safety and tolerability—showing no worsening in PHQ-9 scores and comparable adverse event rates to placebo—vidofludimus calcium presents a differentiated profile that could redefine efficacy benchmarks in PMS, a market where existing therapies largely fail to show meaningful neurological improvement. The commercial opportunity is substantial, as the global MS market is projected to exceed $30 billion by the early 2030s, and vidofludimus calcium's dual mechanism (Nurr1 activation for neuroprotection and DHODH inhibition for anti-inflammatory/antiviral effects) uniquely targets both relapse-associated worsening and progression independent of relapse activity (PIRA), addressing core drivers of long-term disability that current therapies overlook. With top-line data from the pivotal phase 3 ENSURE trials in relapsing MS expected by end-2026 and a clear path to NDA submission in mid-2027, Immunic has derisked near-term catalysts while building a foundation for expansion into PPMS, leveraging the CALLIPER trial's promising signals. The recent appointment of Erik Lundgren as CEO—whose deep MS commercialization experience includes shaping the launch of Ocrevus®—signals a strategic shift toward execution and commercial readiness, directly addressing prior concerns about leadership gaps as the company transitions from R&D to commercial stage. Furthermore, the $200 million upfront private placement (with potential for another $200 million) provides a fortified runway through ENSURE readout, NDA submission, and initial commercialization efforts, alleviating near-term financing concerns and enabling investment in medical and commercial infrastructure ahead of potential approval in 2028.
Immunic's intellectual property strategy creates a durable competitive moat that is underappreciated by the market, with multi-layered patent protection extending well beyond typical industry timelines and supporting long-term exclusivity for vidofludimus calcium. The European Patent Office's grant of EP3713554, building on the USPTO's 2023 allowance, provides protection into 2038 in Europe, with potential Supplementary Protection Certificate (SPC) eligibility pushing exclusivity into 2043. In the United States, existing patents provide protection into 2041, with pending applications targeting use of vidofludimus calcium in neurodegenerative diseases and pharmaceutical formulations that could extend coverage to 2044 and 2045, respectively. This breadth of protection—covering composition-of-matter, indication-specific dosing, polymorphs, and production processes—creates significant barriers to generic entry and design-around attempts, particularly important given the drug's applicability across MS relapsing and progressive forms, as well as potential expansion into neurologic and gastrointestinal indications via IMU-856 and IMU-381. The patent's broad scope, which protects all label-relevant dosing regimens and extends to salts, solvates, and free acid forms, ensures that alternative formulations cannot easily circumvent exclusivity, a critical advantage in a landscape where biologics often face biosimilar pressure and small molecules are vulnerable to patent challenges. This robust IP position not only supports premium pricing potential post-approval but also enhances partnership and licensing opportunities, reducing reliance on solo commercialization efforts. Market focus remains fixated on near-term binary catalysts like ENSURE readout, while overlooking how this IP fortress sustains value creation over a decade-plus horizon, allowing Immunic to recoup R&D investments, fund pipeline expansion, and withstand competitive pressures long after launch. The combination of near-term clinical milestones, strengthening leadership with commercial depth, fortified cash runway, and unprecedented IP durability creates a compelling asymmetric opportunity where the market underestimates both the probability of success and the magnitude of long-term value if vidofludimus calcium achieves regulatory approval.
Immunic is positioned to capitalize on a significant unmet need in progressive multiple sclerosis (PMS) through vidofludimus calcium's demonstrated ability to drive confirmed disability improvement (CDI), not just slow worsening, as highlighted in the CALLIPER trial data. The late-breaking poster at CMSC 2026 introduced the Confirmed Disability Change (CDC) endpoint, which captures both worsening and improvement in a unified framework, revealing consistent favorability for vidofludimus calcium over placebo across ordinal categorical, time-to-event, and Markov state change models. This approach addresses a critical limitation in current MS trial design, where conventional endpoints ignore neuroprotective or restorative effects, potentially underestimating the drug's true benefit. By demonstrating statistically significant CDI alongside favorable safety and tolerability—showing no worsening in PHQ-9 scores and comparable adverse event rates to placebo—vidofludimus calcium presents a differentiated profile that could redefine efficacy benchmarks in PMS, a market where existing therapies largely fail to show meaningful neurological improvement. The commercial opportunity is substantial, as the global MS market is projected to exceed $30 billion by the early 2030s, and vidofludimus calcium's dual mechanism (Nurr1 activation for neuroprotection and DHODH inhibition for anti-inflammatory/antiviral effects) uniquely targets both relapse-associated worsening and progression independent of relapse activity (PIRA), addressing core drivers of long-term disability that current therapies overlook. With top-line data from the pivotal phase 3 ENSURE trials in relapsing MS expected by end-2026 and a clear path to NDA submission in mid-2027, Immunic has derisked near-term catalysts while building a foundation for expansion into PPMS, leveraging the CALLIPER trial's promising signals. The recent appointment of Erik Lundgren as CEO—whose deep MS commercialization experience includes shaping the launch of Ocrevus®—signals a strategic shift toward execution and commercial readiness, directly addressing prior concerns about leadership gaps as the company transitions from R&D to commercial stage. Furthermore, the $200 million upfront private placement (with potential for another $200 million) provides a fortified runway through ENSURE readout, NDA submission, and initial commercialization efforts, alleviating near-term financing concerns and enabling investment in medical and commercial infrastructure ahead of potential approval in 2028.
Immunic's intellectual property strategy creates a durable competitive moat that is underappreciated by the market, with multi-layered patent protection extending well beyond typical industry timelines and supporting long-term exclusivity for vidofludimus calcium. The European Patent Office's grant of EP3713554, building on the USPTO's 2023 allowance, provides protection into 2038 in Europe, with potential Supplementary Protection Certificate (SPC) eligibility pushing exclusivity into 2043. In the United States, existing patents provide protection into 2041, with pending applications targeting use of vidofludimus calcium in neurodegenerative diseases and pharmaceutical formulations that could extend coverage to 2044 and 2045, respectively. This breadth of protection—covering composition-of-matter, indication-specific dosing, polymorphs, and production processes—creates significant barriers to generic entry and design-around attempts, particularly important given the drug's applicability across MS relapsing and progressive forms, as well as potential expansion into neurologic and gastrointestinal indications via IMU-856 and IMU-381. The patent's broad scope, which protects all label-relevant dosing regimens and extends to salts, solvates, and free acid forms, ensures that alternative formulations cannot easily circumvent exclusivity, a critical advantage in a landscape where biologics often face biosimilar pressure and small molecules are vulnerable to patent challenges. This robust IP position not only supports premium pricing potential post-approval but also enhances partnership and licensing opportunities, reducing reliance on solo commercialization efforts. Market focus remains fixated on near-term binary catalysts like ENSURE readout, while overlooking how this IP fortress sustains value creation over a decade-plus horizon, allowing Immunic to recoup R&D investments, fund pipeline expansion, and withstand competitive pressures long after launch. The combination of near-term clinical milestones, strengthening leadership with commercial depth, fortified cash runway, and unprecedented IP durability creates a compelling asymmetric opportunity where the market underestimates both the probability of success and the magnitude of long-term value if vidofludimus calcium achieves regulatory approval.
Immunic faces substantial execution risk in translating promising phase 2 signals into successful phase 3 outcomes for vidofludimus calcium, particularly given the high failure rate in neurodegenerative trials and the absence of validated biomarkers for neuroprotective effects in MS. While the CALLIPER trial showed statistically significant 24-week confirmed disability improvement (24wCDI) and reductions in confirmed disability worsening (24wCDW) in progressive MS, these were exploratory post-hoc analyses in a phase 2 study not powered for definitive efficacy conclusions, raising concerns about reproducibility in larger, pivotal trials. The company's reliance on a novel composite endpoint (Confirmed Disability Change or CDC) introduced at CMSC 2026—while scientifically intriguing—lacks regulatory precedent and may not be accepted by the FDA or EMA as a primary basis for approval, potentially requiring costly trial redesigns or additional data generation if conventional endpoints fail to show significance. Furthermore, the safety profile, though favorable relative to placebo in CALLIPER, remains based on limited long-term exposure (only 467 patients treated up to 120 weeks), with no data beyond two years to assess risks of delayed adverse events, particularly given vidofludimus calcium's mechanism involving DHODH inhibition, which has been associated with teratogenicity and hematopoietic effects in other drugs. The transition to commercial stage under new CEO Erik Lundgren introduces unproven execution risk; while his Ocrevus® launch experience is notable, Immunic's organizational infrastructure, commercial capabilities, and go-to-market readiness are untested, and the shift from a science-led to commercial-driven model could create internal misalignment, especially as Dr. Vitt retains scientific strategy oversight. The $200 million upfront financing, while substantial, may prove insufficient if ENSURE trials encounter delays, require expansion, or if unexpected costs arise in NDA preparation or launch readiness, especially given the company's history of rising operating expenses—R&D increased to $25.6 million in Q1 2026 from $21.5 million in Q1 2025, and G&A rose to $7.6 million from $5.3 million—suggesting burn rate acceleration that could exhaust funds before milestones are met. With no recent earnings call transcript available, management's discussion of risks, contingencies, or sensitivity analyses is absent, leaving investors to rely solely on optimistic forward-looking statements without insight into how challenges are being mitigated.
Immunic faces substantial execution risk in translating promising phase 2 signals into successful phase 3 outcomes for vidofludimus calcium, particularly given the high failure rate in neurodegenerative trials and the absence of validated biomarkers for neuroprotective effects in MS. While the CALLIPER trial showed statistically significant 24-week confirmed disability improvement (24wCDI) and reductions in confirmed disability worsening (24wCDW) in progressive MS, these were exploratory post-hoc analyses in a phase 2 study not powered for definitive efficacy conclusions, raising concerns about reproducibility in larger, pivotal trials. The company's reliance on a novel composite endpoint (Confirmed Disability Change or CDC) introduced at CMSC 2026—while scientifically intriguing—lacks regulatory precedent and may not be accepted by the FDA or EMA as a primary basis for approval, potentially requiring costly trial redesigns or additional data generation if conventional endpoints fail to show significance. Furthermore, the safety profile, though favorable relative to placebo in CALLIPER, remains based on limited long-term exposure (only 467 patients treated up to 120 weeks), with no data beyond two years to assess risks of delayed adverse events, particularly given vidofludimus calcium's mechanism involving DHODH inhibition, which has been associated with teratogenicity and hematopoietic effects in other drugs. The transition to commercial stage under new CEO Erik Lundgren introduces unproven execution risk; while his Ocrevus® launch experience is notable, Immunic's organizational infrastructure, commercial capabilities, and go-to-market readiness are untested, and the shift from a science-led to commercial-driven model could create internal misalignment, especially as Dr. Vitt retains scientific strategy oversight. The $200 million upfront financing, while substantial, may prove insufficient if ENSURE trials encounter delays, require expansion, or if unexpected costs arise in NDA preparation or launch readiness, especially given the company's history of rising operating expenses—R&D increased to $25.6 million in Q1 2026 from $21.5 million in Q1 2025, and G&A rose to $7.6 million from $5.3 million—suggesting burn rate acceleration that could exhaust funds before milestones are met. With no recent earnings call transcript available, management's discussion of risks, contingencies, or sensitivity analyses is absent, leaving investors to rely solely on optimistic forward-looking statements without insight into how challenges are being mitigated.